Don’t miss – Page 119 – Endpoints News

SIGN UP

Idera squelches any lingering enthusiasm as its lead TLR9 drug flunks PhIII — badly

Last year

UPDATED: Inside Novartis' months-long efforts to scale their rivals' Covid-19 vaccines

Last year

Catalent amps up plans to manufacture J&J's Covid-19 vaccine, adding vial filling line in Italy

Last year

UPDATED: Living in its post-Shire world, Takeda continues aggressive licensing push in $2.3B deal with Anima

Last year

Top biotech investor Peter Kolchinsky tees up a new SPAC — 3 days after a $300M raise for radiopharmaceuticals play

Last year

Roger Perlmutter’s latest ‘retirement’ gig opens a door to the bustling China biotech scene

Last year

Got a revolutionary healthcare company? Bob Nelsen, Jeff Leiden’s SPAC has $500M to take it public

Last year

Little Apellis is arming itself for a David and Goliath battle over a blockbuster drug franchise

Last year

Denied top job, Mike Nally exits chief marketing job at Merck as the big C-suite shakeup continues

Last year

Dean Li invites another under-the-radar biotech to Merck's dealmaking table as Amathus signs neurodegeneration pact

Last year

After a roller coaster ride, Sage COO strikes out on his own to chart a new biotech path

Last year

Another bluebird exec jumps ship as questions swirl over gene therapies and imminent split

Last year

FTC pledges to aggressively crack down on pharma mergers

Last year

Can a CRISPR startup succeed where Pfizer, GlaxoSmithKline, Biogen and Genentech failed and cure chronic pain?

Last year

Takeda, Sarepta double down on a biotech partner's platform to engineer better AAV capsids by mapping out their structure

Last year

No quick redemption for GlaxoSmithKline’s $4B alliance with Merck KGaA as bispecific cancer drug flunks a second trial

Last year

UPDATED: Solid Bio’s long, troubled slog through the clinic yields 'encouraging' early data and no new safety concerns. It's not winning over investors yet

Last year

BIO chair slams Trump’s HHS, calls to stop Russian disinformation campaign on vaccines

Last year

Daphne Koller lines up $400M for a global shopping spree to vault forward on AI drug discovery

Last year

Gilead, Merck put aside rivalry to challenge GlaxoSmithKline for long-acting HIV meds

Last year

ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

Last year

On a roll, Regeneron and Sanofi boast positive PhIII OS results in 'notoriously' tough cancer

Last year

Novartis' wild card blockbuster contender falls flat; Regulatory reckoning for checkpoint drugs looms; and more

Last year

Prometheus and Longboard make the leap to Nasdaq with 9-figure offerings and are joined by a Falcon Edge-backed SPAC

Last year

First page Previous page 116 117 118119120 121 122 Next page Last page